JLJeong Ho Lee

Jeong Ho Lee

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jeong Ho Lee has a total of 298 co-authors. Here are the top co-authors by number of shared publications:

  • Dong Seok Kim

    Department of Neurosurgery, Yonsei University College of Medicine , Seoul 03722

    9 shared publications
  • Sangwoo Kim

    Department of Biomedical Systems Informatics, Yonsei University College of Medicine, Seoul, Republic of Korea

    9 shared publications
  • Jae Seok Lim

    Graduate School of Medical Science and Engineering, KAIST, Daejeon, 34141, South Korea

    8 shared publications
  • Se-Hoon Lee

    Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

    8 shared publications
  • Seok-Gu Kang

    Department of Neurosurgery, Brain Tumor Center, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea

    8 shared publications
  • Hoon-Chul Kang

    Department of Pediatrics, Yonsei University College of Medicine , Seoul 03722

    7 shared publications

Latest Publications

  • Open Access

    Putative glioblastoma origin-like cells in the subventricular zone: isolation and characterization

    by Hyeong-Cheol Oh, Ran Joo Choi, Se-Young Jo, Eunchae Yeo, Euna Jo, Jin-Kyoung Shim, Kibyeong Kim, Seo Jin Kim, Hye Joung Cho, Hyun Jung Kim, et al.

    Glioblastoma (GBM) remains lethal despite maximal therapy. The adult subventricular zone (SVZ), a neural stem-cell niche, has been implicated as a potential site of origin, yet the identity and functional properties of putative GBM origin-like cells (GBM-OCs) within the SVZ remain unclear. An SVZ-restricted somatic mutation mouse model (Cre-induced EGFRvIII expression with Trp53 and Pten disruption) was established and mouse SVZ-derived cells were prospectively isolated for functional and molecular profiling. Self-renewal, multipotency, invasive potential and tumour-initiating capacity were assessed relative to control SVZ cells and matched tumour-derived tumourspheres. Whole-genome and RNA sequencing defined genomic and transcriptional alterations during early progression. Mouse GBM-OCs exhibited self-renewal and multilineage differentiation and initiated tumours only after re-implantation into the SVZ (11/29, 38%), whereas direct striatal implantation failed (0/25, 0%), indicating context-dependent tumorigenic potential associated with the SVZ microenvironment. In contrast, tumour-derived tumourspheres retained tumorigenic capacity upon implantation into both the SVZ and the striatum. During progression from mouse GBM-OCs to tumours, whole-chromosome and arm-level aneuploidies accumulated. In patients with GBM, multi-region single-nucleus RNA sequencing of tumour-free SVZ, matched tumours and tumour-free cortex identified rare neural stem cell-like, astrocyte-like and oligodendrocyte precursor-like SVZ populations transcriptionally aligned with GBM programmes. These cells showed single-nucleus RNA-inferred chromosome 7 gain and/or chromosome 10 loss signals, with concordant low-frequency copy-number alterations in the SVZ detected by exome sequencing and enriched in matched tumours. Together, these findings support the presence of SVZ-resident stem or progenitor-like populations with early GBM-associated features, consistent with putative GBM-OCs, and highlight the SVZ niche as a potential target for early detection and niche-informed therapeutic strategies.

  • Top Cited Papers

    IDH-mutant gliomas arise from glial progenitor cells harboring the initial driver mutation

    by Jung Won Park, Jiehoon Kwak, Keon-Woo Kim, Saehoon Jung, Chang Hyun Nam, Hyun Jung Kim, Sang Mee Lee, Chanho Choi, Yongjin Ahn, Ji-Hyung Park, et al.

    Identifying the cell of origin that harbors an initial driver mutation is key to understanding tumor evolution and for the development of new treatments. For isocitrate dehydrogenase (IDH)–mutant gliomas, the most common malignant primary brain tumor in young adults, the cell of origin is currently poorly understood. We conducted deep sequencing on 142 tissues from 70 individuals comprising tumors, peritumoral cortex or subventricular zones, and blood. Low-level IDH mutations were found in the peritumoral cortex in 37.9% (11 of 29) of patients. Integrating cell-type–specific mutation analysis, the direction of clonal evolution, spatial transcriptomics from patient brains, and a cancer mouse model arising from mutant oligodendrocyte progenitor cell, we determined that glial progenitor cells harboring an initial IDH mutation were responsible for the development of IDH-mutant gliomas.


  • White Matter Injury Fuels Early Progression of Glioblastoma

    by Keon Woo Kim, Hyun Jin Choi, Jeong Ho Lee

    Glioblastoma (GBM) is the most aggressive and devastating primary brain cancer in adults. Most GBMs are diagnosed at an advanced stage with therapy resistance, posing a major obstacle to understanding the tumor microenvironment (TME) at the earliest stages of disease development. A precise characterization of early-stage GBM and its TME could provide critical insights into tumor progression and inform new therapeutic strategies. In a recent issue of Nature, Clements and colleagues demonstrated that white matter (WM) injury, induced by early tumor cells, constitutes a key TME factor driving GBM progression. Using somatic mouse models, patient-derived xenografts, and human tissues, they showed that early glioma cells preferentially infiltrate WM tracts, inducing sterile alpha and TIR motif–containing 1–mediated Wallerian degeneration that propagates into distal WM regions. Remarkably, WM injury induced by axonal transection significantly accelerated GBM progression at distal sites, whereas this effect was abolished by Sarm1 knockout, confirming that axonal injury followed by Wallerian degeneration drives distal tumor progression. Collectively, these findings reveal a previously unrecognized evolutionary process in GBM development and highlight potential targets for therapeutic intervention.


  • Open Access

    Data from Precancerous Cells Initiate Glioblastoma Evolution and Contribute to Intratumoral Heterogeneity

    by Hyun Jung Kim, Keon Woo Kim, Do Hyeon Cha, Jihwan Yoo, Eui Hyun Kim, Jong Hee Chang, Seok-Gu Kang, Jung Won Park, Ja Hye Kim, Yeonhee Lee, et al.

    Neural stem cells in the subventricular zone are identified as cells of origin harboring driver mutations in glioblastoma (GBM), which is the most devastating brain tumor with highly heterogeneous nature. However, the sequential transformation of a limited number of mutation-harboring neural stem cells into a distant tumor with high intratumoral heterogeneity remains poorly understood. In this study, we have identified transcriptionally distinct types of mutation-harboring precancerous cells in our spontaneous, somatic mouse model recapitulating human GBM evolution as well as in tumor-free subventricular zone tissues from patients. These precancerous cells emerge via oligodendrocyte lineage specification, exhibiting unique transcriptional programs involving dysregulated translations and extracellular matrix remodeling. Subsequently, they give rise to heterogeneous tumor cell populations by activating multiple programs crucial for gliomagenesis. Our findings highlight the pivotal role of precancerous cells in tumor evolution and intratumoral heterogeneity, suggesting their potential as a novel therapeutic target for GBM.Significance:We identified mutation-harboring precancerous cells that emerge via oligodendrocyte progenitor cell fate specification and contribute to the evolution of GBM with intratumoral molecular heterogeneity. This single-cell atlas from the GBM mouse model and patients’ tissues revealed distinct transitional states of precancerous cells and demonstrated step-wise acquisition of oncogenic programs during GBM progression.See related commentary by Lee and Suvà, p. 1312

  • Open Access

    Supplementary Figures S1-S15 from Precancerous Cells Initiate Glioblastoma Evolution and Contribute to Intratumoral Heterogeneity

    by Hyun Jung Kim, Keon Woo Kim, Do Hyeon Cha, Jihwan Yoo, Eui Hyun Kim, Jong Hee Chang, Seok-Gu Kang, Jung Won Park, Ja Hye Kim, Yeonhee Lee, et al.

    Supplementary Figure S1. Enrichment of mutation-harboring cells during GBM evolution in the spontaneous GBM mouse model. Supplementary Figure S2. The quality control and pre-processing of single-cell RNA-seq data. Supplementary Figure S3. Characterization of unknown cell clusters. Supplementary Figure S4. Classification of precancerous and cancer cell clusters with associated gene modules. Supplementary Figure S5. Classification of precancerous and cancer cell clusters using single-cell multiome sequencing. Supplementary Figure S6. Classification of cancer cell clusters using single-cell RNA sequencing. Supplementary Figure S7. Changes in cell-cell interaction analyses between precancer and cancer stages. Supplementary Figure S8. Fluorescent in situ hybridization of precancerous cell markers. Supplementary Figure S9. Proliferation analysis after Gap43 and Ccnd1 siRNA treatment. Supplementary Figure S10. Clinical characteristics of GBM patients. Supplementary Figure S11. Single-cell analysis of SVZ and tumor from each patient. Supplementary Figure S12. Characterization of human cell types and unknown cell population. Supplementary Figure S13. Variant allele frequencies of driver mutations. Supplementary Figure S14. Copy number analysis for Pre-CC and CC in patient #1. Supplementary Figure S15. Copy number analysis for Pre-CC and CC in patient #2.

  • Precancerous Cells Initiate Glioblastoma Evolution and Contribute to Intratumoral Heterogeneity

    by Hyun Jung Kim, Keon Woo Kim, Do Hyeon Cha, Jihwan Yoo, Eui Hyun Kim, Jong Hee Chang, Seok-Gu Kang, Jung Won Park, Ja Hye Kim, Yeonhee Lee, et al.

    Neural stem cells in the subventricular zone are identified as cells of origin harboring driver mutations in glioblastoma (GBM), which is the most devastating brain tumor with highly heterogeneous nature. However, the sequential transformation of a limited number of mutation-harboring neural stem cells into a distant tumor with high intratumoral heterogeneity remains poorly understood. In this study, we have identified transcriptionally distinct types of mutation-harboring precancerous cells in our spontaneous, somatic mouse model recapitulating human GBM evolution as well as in tumor-free subventricular zone tissues from patients. These precancerous cells emerge via oligodendrocyte lineage specification, exhibiting unique transcriptional programs involving dysregulated translations and extracellular matrix remodeling. Subsequently, they give rise to heterogeneous tumor cell populations by activating multiple programs crucial for gliomagenesis. Our findings highlight the pivotal role of precancerous cells in tumor evolution and intratumoral heterogeneity, suggesting their potential as a novel therapeutic target for GBM. Significance: We identified mutation-harboring precancerous cells that emerge via oligodendrocyte progenitor cell fate specification and contribute to the evolution of GBM with intratumoral molecular heterogeneity. This single-cell atlas from the GBM mouse model and patients’ tissues revealed distinct transitional states of precancerous cells and demonstrated step-wise acquisition of oncogenic programs during GBM progression. See related commentary by Lee and Suvà, p. 1312


  • Open Access

    Distant origin of glioblastoma recurrence: neural stem cells in the subventricular zone serve as a source of tumor reconstruction after primary resection

    by Xue Li, Hyun Jung Kim, Jihwan Yoo, Yeonhee Lee, Chang Hyun Nam, Jonghan Park, Soon-Tae Lee, Tae Min Kim, Seung Hong Choi, Jae-Kyung Won, et al.

    Glioblastoma (GBM) is the most aggressive and common type of primary malignant brain cancer in adults. GBM often recurs locally near the resection cavity (RC) following the surgical removal of primary tumors. Recent research has reported that neural stem cells (NSCs) in the subventricular zone (SVZ) harboring cancer-driving mutations serve as the cells of origin for human GBM. However, the pathological role of tumor-initiating NSCs in the SVZ in tumor recurrence remains to be elucidated. Here, we explore the potential contribution of mutation-harboring NSCs in the SVZ to tumor recurrence around the RC following surgical resection. Our hypothesis emerged from performing deep sequencing of longitudinal tissues from 10 patients with GBM, including (i) tumor-free SVZ tissue, (ii) primary tumor tissue, (iii) recurrent tumor tissue, and (iv) blood. As a result of this sequencing, we observed evidence suggesting that recurrent tumors show genetic links to the SVZ in 60% (6/10) of patients, which are distinct from the primary tumors. Using a genome-edited mouse model, we further identified that mutation-harboring NSCs appeared to migrate to the RC through the aberrant growth of oligodendrocyte progenitor cells, potentially contributing to the reconstruction of high-grade malignant gliomas in the RC. This process was associated with the CXCR4/CXCL12 axis, as supported by RNA sequencing data from human recurrent GBM. Taken together, our findings suggest that NSCs in human SVZ tissue may play a role in GBM recurrence, potentially highlighting a novel distant contributor of recurrence.


  • Open Access

    Low-level brain somatic mutations in exonic regions are collectively implicated in autism with germline mutations in autism risk genes

    by Il Bin Kim, Myeong-Heui Kim, Saehoon Jung, Woo Kyeong Kim, Junehawk Lee, Young Seok Ju, Maree J. Webster, Sanghyeon Kim, Ja Hye Kim, Hyun Jung Kim, et al.

    Low-level somatic mutations in the human brain are implicated in various neurological disorders. The contribution of low-level brain somatic mutations to autism spectrum disorder (ASD), however, remains poorly understood. Here, we performed high-depth exome sequencing with an average read depth of 559.3x in 181 cortical, cerebellar, and peripheral tissue samples to identify brain somatic single nucleotide variants (SNVs) in 24 ASD subjects and 31 controls. We detected ~2.4 brain somatic SNVs per exome per single brain region, with a variant allele frequency (VAF) as low as 0.3%. The mutational profiles, including the number, signature, and type, were not significantly different between the ASD patients and controls. Intriguingly, when considering genes with low-level brain somatic SNVs and ASD risk genes with damaging germline SNVs together, the merged set of genes carrying either somatic or germline SNVs in ASD patients was significantly involved in ASD-associated pathophysiology, including dendrite spine morphogenesis (p = 0.025), mental retardation (p = 0.012), and intrauterine growth retardation (p = 0.012). Additionally, the merged gene set showed ASD-associated spatiotemporal expression in the early and mid-fetal cortex, striatum, and thalamus (all p < 0.05). Patients with damaging mutations in the merged gene set had a greater ASD risk than did controls (odds ratio = 3.92, p = 0.025, 95% confidence interval = 1.12–14.79). The findings of this study suggest that brain somatic SNVs and germline SNVs may collectively contribute to ASD-associated pathophysiology.


  • Threshold of somatic mosaicism leading to brain dysfunction with focal epilepsy

    by Jintae Kim, Sang Min Park, Hyun Yong Koh, Ara Ko, Hoon-Chul Kang, Won Seok Chang, Dong Seok Kim, Jeong Ho Lee

    Somatic mosaicism in a fraction of brain cells causes neurodevelopmental disorders, including childhood intractable epilepsy. However, the threshold for somatic mosaicism leading to brain dysfunction is unknown. In this study, we induced various mosaic burdens in focal cortical dysplasia type II (FCD II) mice, featuring mTOR somatic mosaicism and spontaneous behavioural seizures. The mosaic burdens ranged from approximately 1000 to 40 000 neurons expressing the mTOR mutant in the somatosensory or medial prefrontal cortex. Surprisingly, approximately 8000–9000 neurons expressing the MTOR mutant, extrapolated to constitute 0.08%–0.09% of total cells or roughly 0.04% of variant allele frequency in the mouse hemicortex, were sufficient to trigger epileptic seizures. The mutational burden was correlated with seizure frequency and onset, with a higher tendency for electrographic inter-ictal spikes and beta- and gamma-frequency oscillations in FCD II mice exceeding the threshold. Moreover, mutation-negative FCD II patients in deep sequencing of their bulky brain tissues revealed somatic mosaicism of the mTOR pathway genes as low as 0.07% in resected brain tissues through ultra-deep targeted sequencing (up to 20 million reads). Thus, our study suggests that extremely low levels of somatic mosaicism can contribute to brain dysfunction.


  • Open Access

    Threshold of somatic mosaicism disrupting the brain function

    by Jintae Kim, Sang Min Park, Hyun Yong Koh, Ara Ko, Hoon-Chul Kang, Won Seok Chang, Dong Seok Kim, Jeong Ho Lee

    Somatic mosaicism in a fraction of brain cells causes neurodevelopmental disorders, including childhood intractable epilepsy. However, the threshold for somatic mosaicism leading to brain dysfunction is unknown. In this study, we induced various mosaic burdens in mice of focal cortical dysplasia type II (FCD II), featuring mTOR somatic mosaicism and spontaneous behavioral seizures. Mosaic burdens ranged from approximately 1,000 to 40,000 neurons expressing the mTOR mutant in the somatosensory (SSC) or medial prefrontal (PFC) cortex. Surprisingly, just ∼8,000-9,000 neurons expressing the MTOR mutant were sufficient to trigger epileptic seizures. Mutational burden correlated with seizure frequency and onset, with a higher tendency for electrographic inter-ictal spikes and beta- and gamma-frequency oscillations in FCD II mice exceeding the threshold. Moreover, mutation-negative FCD II patients in deep sequencing of their bulky brain tissues revealed somatic mosaicism of mTOR pathway genes as low as 0.07% in resected brain tissues through ultra-deep targeted sequencing (up to 20 million reads). Thus, our study suggests that extremely low levels of somatic mosaicism can contribute to brain dysfunction.